Deutsche Bank Ag\ Ocular Therapeutix, Inc Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Deutsche Bank Ag\ holds 833,574 shares of OCUL stock, worth $7.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

833,574

Previous 807,310 3.25%

Holding current value

$7.52 Million

Previous $5.52 Million 31.33%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$6.45 - $9.23 $169,402 - $242,416	26,264 Added 3.25%	833,574 $7.25 Million
Q2 2024 Aug 14, 2024	BUY	$4.2 - $8.69 $41,084 - $85,005	9,782 Added 1.23%	807,310 $5.52 Million
Q1 2024 May 15, 2024	BUY	$3.85 - $10.93 $2.94 Million - $8.34 Million	762,889 Added 2202.4%	797,528 $7.26 Million
Q4 2023 Feb 14, 2024	SELL	$2.08 - $4.52 $2,427 - $5,274	-1,167 Reduced 3.26%	34,639 $154,000
Q3 2023 Nov 09, 2023	BUY	$3.14 - $5.04 $18,726 - $30,058	5,964 Added 19.99%	35,806 $112,000
Q2 2023 Aug 14, 2023	SELL	$4.6 - $7.64 $97,671 - $162,220	-21,233 Reduced 41.57%	29,842 $153,000
Q1 2023 May 15, 2023	BUY	$2.79 - $6.27 $45,136 - $101,436	16,178 Added 46.36%	51,075 $269,000
Q4 2022 Feb 13, 2023	BUY	$2.61 - $4.41 $1,344 - $2,271	515 Added 1.5%	34,897 $98,000
Q3 2022 Nov 14, 2022	SELL	$4.09 - $6.5 $21,047 - $33,449	-5,146 Reduced 13.02%	34,382 $143,000
Q2 2022 Aug 11, 2022	SELL	$3.01 - $5.22 $15,817 - $27,431	-5,255 Reduced 11.73%	39,528 $159,000
Q1 2022 May 13, 2022	SELL	$4.83 - $7.35 $22,710 - $34,559	-4,702 Reduced 9.5%	44,783 $222,000
Q4 2021 Feb 11, 2022	SELL	$6.16 - $12.07 $12,166 - $23,838	-1,975 Reduced 3.84%	49,485 $344,000
Q3 2021 Nov 04, 2021	SELL	$9.7 - $14.34 $49,149 - $72,660	-5,067 Reduced 8.96%	51,460 $514,000
Q2 2021 Aug 11, 2021	BUY	$13.43 - $19.16 $48,415 - $69,071	3,605 Added 6.81%	56,527 $802,000
Q1 2021 May 13, 2021	SELL	$15.82 - $22.11 $132,492 - $185,171	-8,375 Reduced 13.66%	52,922 $868,000
Q4 2020 Feb 16, 2021	SELL	$7.91 - $22.95 $792,866 - $2.3 Million	-100,236 Reduced 62.05%	61,297 $1.27 Million
Q3 2020 Nov 12, 2020	BUY	$7.36 - $9.87 $403,033 - $540,481	54,760 Added 51.29%	161,533 $1.23 Million
Q2 2020 Aug 13, 2020	BUY	$4.67 - $8.95 $430,237 - $824,545	92,128 Added 629.07%	106,773 $890,000
Q1 2020 May 14, 2020	SELL	$3.95 - $7.4 $2,776 - $5,202	-703 Reduced 4.58%	14,645 $73,000
Q4 2019 Feb 14, 2020	BUY	$2.57 - $4.73 $9,385 - $17,273	3,652 Added 31.22%	15,348 $59,000
Q3 2019 Nov 14, 2019	SELL	$3.04 - $5.32 $48,940 - $85,646	-16,099 Reduced 57.92%	11,696 $34,000
Q2 2019 Aug 14, 2019	SELL	$2.46 - $4.52 $37,497 - $68,898	-15,243 Reduced 35.42%	27,795 $120,000
Q1 2019 May 15, 2019	BUY	$3.51 - $4.77 $9,396 - $12,769	2,677 Added 6.63%	43,038 $168,000
Q4 2018 Feb 14, 2019	SELL	$3.87 - $7.11 $137,957 - $253,457	-35,648 Reduced 46.9%	40,361 $159,000
Q3 2018 Dec 21, 2021	BUY	$5.42 - $6.99 $47,679 - $61,491	8,797 Added 13.09%	76,009 $522,000
Q3 2018 Nov 14, 2018	BUY	$5.42 - $6.99 $25,582 - $32,992	4,720 Added 7.55%	67,212 $461,000
Q2 2018 Apr 21, 2020	BUY	$5.99 - $8.17 $62,715 - $85,539	10,470 Added 20.13%	62,492 $422,000
Q2 2018 Aug 14, 2018	BUY	$5.99 - $8.17 $85,621 - $116,781	14,294 Added 37.89%	52,022 $349,000
Q1 2018 Oct 18, 2019	BUY	$4.66 - $7.08 $31,636 - $48,066	6,789 Added 21.94%	37,728 $243,000
Q1 2018 May 15, 2018	SELL	$4.66 - $7.08 $89,127 - $135,412	-19,126 Reduced 38.2%	30,939 $199,000
Q4 2017 Feb 14, 2018	BUY	$3.73 - $6.37 $111,668 - $190,705	29,938 Added 148.75%	50,065 $221,000
Q3 2017 Nov 14, 2017	BUY	$5.28 - $6.88 $106,270 - $138,473	20,127	20,127 $122,000

Others Institutions Holding OCUL

# of Institutions

172

Shares Held

138M

Call Options Held

150K

Put Options Held

225K

View Full List

About OCULAR THERAPEUTIX, INC

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $694M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

More about OCUL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account